Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT03801434
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • BCR-JAK2 Fusion Protein Expression
  • Blasts 20 Percent or Less of Peripheral Blood White Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Peripheral Blood White Cells
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified
  • Eosinophilia
  • Hepatomegaly
  • Hypereosinophilic Syndrome
  • JAK2 Gene Mutation
  • Splenomegaly
  • TEL-JAK2 Fusion Protein Expression

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Key Dates

First listed
Jan 11, 2019
Start date
Nov 15, 2019
Status verified
Aug 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ruxolitinib)
    Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 3 years ]

Locations (4)

FacilityCityStateZIPSite coordinators
Stanford Cancer Institute Palo AltoPalo AltoCalifornia94304-
OHSU Knight Cancer InstitutePortlandOregon97201-
University of UtahSalt Lake CityUtah84112-
Fred Hutchinson cancer research centerSeattleWashington98109-

Find similar trials in Palo Alto, CA

By research site
Stanford Cancer Institute Palo Alto· Palo Alto, CAOHSU Knight Cancer Institute· Portland, ORUniversity of Utah· Salt Lake City, UTFred Hutchinson cancer research center· Seattle, WA

Related Studies